2096513-89-0
2096513-89-0
Chemical Structure
Tilavonemab
Synonym(s): ABBV-8E12; C2N-8E12
- CAS No.: 2096513-89-0
- Formula:N/A
- Molecular Weight:(145 kDa)
SMILES: [Tilavonemab]
Biological Activity: Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tilavonemab | 99.59% | Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vaswani P A, et al. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020 Aug;33(4):527-533. [Content Brief]
- [2]. Lopez-Cuina M, et al. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders[J]. Revue Neurologique, 2022, 178(5): 460-471. [Content Brief]
- [3]. Neațu M, et al. Monoclonal antibody therapy in Alzheimer’s disease[J]. Pharmaceutics, 2023, 16(1): 60. [Content Brief]
Keywords
